Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study


REDWOOD CITY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announce compelling results from in vivo studies of icovamenib in combination with semaglutide.

See the original post here:
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Related Posts